TORONTO, ONTARIO--(Marketwired - Nov. 3, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company's programs and progress at several upcoming conferences in 2016.

Investor Conference:

• Oppenheimer Life Sciences Summit
  Attendee: Niclas Stiernholm, PhD, Trillium Chief Executive Officer
  Date and Time: Nov. 29, 2016
  Location: Sofitel Hotel, New York City

Scientific Conferences:

• The Society for Immunotherapy of Cancer (SITC) 31^st Annual Meeting
  Presenter: Lisa Johnson, PhD, Trillium Research Scientist
  Title: CD47 is Overexpressed on Merkel Cell Carcinoma and a Target for SIRPαFc Therapy
  Date and Time: Nov. 11, 2016, 12:15 - 1:30 p.m. and 6:15 - 7:30 p.m. ET
  Location: Gaylord National Hotel & Convention Center, National Harbor, MD

• American Society of Hematology (ASH) 58^th Annual Meeting
  Presenter: Stephen Ansell, MD, Division of Hematology, Mayo Clinic
  Title: A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
  Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma - Clinical Studies: Poster I
  Date and Time: Dec. 3, 2016, 5:30 - 7:30 p.m. PT
  Location: San Diego Convention Center, Hall GH, San Diego
  
  Presenter: Zezhou Wang, PhD, Trillium Research Scientist
  Title: TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma
  Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
  Date and Time: Dec. 3, 2016, 5:30 - 7:30 p.m. PT
  Location: San Diego Convention Center, Hall GH, San Diego
  
  Presenter: Jaehyun Choi, PhD, Trillium Research Scientist
  Title: Preclinical Characterization of TTI-281, a Novel, Orally Bioavailable BET Inhibitor: Predictive Biomarker Identification and Combination Treatment Analysis
  Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster III
  Date and Time: Dec. 5, 2016, 6:00 - 8:00 p.m. PT
  Location: San Diego Convention Center, Hall GH, San Diego

About Trillium Therapeutics

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing in advanced hematologic malignancies, and a second Phase 1 trial is underway in solid tumors (NCT02890368). Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information

This press release may contain forward-looking statements, which reflect Trillium's current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company's ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.